Literature DB >> 16083325

Malaria vaccines in development.

W Ripley Ballou1.   

Abstract

The recent infusion of public and private funding for malaria vaccine development has greatly accelerated the pace at which candidate malaria vaccines are entering the clinic. Recent promising results from vaccine trials carried out in malaria-naive and -endemic populations have revealed important insights into what will be required of a successful vaccine. Significant challenges lie ahead, not the least of which is insuring access of a malaria vaccine to the populations that need it most. Creative strategies, strong partnerships with developing countries, industry-like approaches to product development, and political vision and leadership on the part of wealthy nations will be critical to the successful implementation of this important new tool to reduce the intolerable burden of malaria.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16083325     DOI: 10.1517/14728214.10.3.489

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN: 1472-8214            Impact factor:   4.191


  7 in total

1.  Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites.

Authors:  Satish Mishra; Urvashi Rai; Takayuki Shiratsuchi; Xiangming Li; Yannick Vanloubbeeck; Joe Cohen; Ruth S Nussenzweig; Elizabeth A Winzeler; Moriya Tsuji; Victor Nussenzweig
Journal:  Vaccine       Date:  2011-07-30       Impact factor: 3.641

2.  Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A.

Authors:  Clara Brando; Lisa A Ware; Helen Freyberger; April Kathcart; Arnoldo Barbosa; Sylvie Cayphas; Marie-Ange Demoitie; Pascal Mettens; D Gray Heppner; David E Lanar
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

3.  Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice.

Authors:  Lisa A Purcell; Stephanie K Yanow; Moses Lee; Terry W Spithill; Ana Rodriguez
Journal:  Infect Immun       Date:  2008-01-03       Impact factor: 3.441

4.  Genetic diversity of Plasmodium vivax and Plasmodium falciparum in Honduras.

Authors:  Ana Cecilia Lopez; Andres Ortiz; Jorge Coello; Wilfredo Sosa-Ochoa; Rosa E Mejia Torres; Engels I Banegas; Irina Jovel; Gustavo A Fontecha
Journal:  Malar J       Date:  2012-11-26       Impact factor: 2.979

5.  Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens.

Authors:  Walter R Weiss; Anita Kumar; George Jiang; Jackie Williams; Anthony Bostick; Solomon Conteh; David Fryauff; Joao Aguiar; Manmohan Singh; Derek T O'Hagan; Jeffery B Ulmer; Thomas L Richie
Journal:  PLoS One       Date:  2007-10-24       Impact factor: 3.240

6.  Plasmodium falciparum merozoite surface protein 1 block 2 gene polymorphism in field isolates along the slope of mount Cameroon: a cross - sectional study.

Authors:  Tobias O Apinjoh; Rolland B Tata; Judith K Anchang-Kimbi; Hanesh F Chi; Eleanor M Fon; Regina N Mugri; Delphine A Tangoh; Robert V Nyingchu; Stephen M Ghogomu; Theresa Nkuo-Akenji; Eric A Achidi
Journal:  BMC Infect Dis       Date:  2015-08-05       Impact factor: 3.090

7.  Commentary in reply to a publication on Plasmodium falciparum pre-erythrocytic stage vaccine development.

Authors:  François P Roman; Margherita Coccia; Lode Schuerman
Journal:  Malar J       Date:  2020-07-20       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.